Bluebird Bio, Inc. (BLUE)
Stock Price:
$62.49 USD
-3.28 (-4.99%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $64.49 +2.00 (3.20%) Aug 11, 5:58 PM
Key Info
| Market Cap |
4.14B |
| Revenue (ttm) |
239.66M |
| Net Income (ttm) |
-653.46M |
| Shares Out |
66.22M |
| EPS (ttm) |
-11.53 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$62.49 |
| Previous Close |
$65.77 |
| Change ($) |
-3.28 |
| Change (%) |
-4.99% |
| Day's Open |
65.99 |
| Day's Range |
62.30 - 66.06 |
| Day's Volume |
600,837 |
| 52-Week Range |
38.95 - 126.39 |
More Stats
| Market Cap |
4.14B |
| Enterprise Value |
2.78B |
| Earnings Date (est) |
Oct 28, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
66.22M |
| Float |
65.90M |
| EPS (basic) |
-11.77 |
| EPS (diluted) |
-11.53 |
| FCF / Share |
-8.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7.35M |
| Short Ratio |
6.28 |
| Short % of Float |
19.97% |
| Beta |
2.31 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
17.27 |
| PB Ratio |
2.59 |
| Revenue |
239.66M |
| Operating Income |
-672.85M |
| Net Income |
-653.46M |
| Free Cash Flow |
-487.32M |
| Net Cash |
1.35B |
| Net Cash / Share |
20.44 |
| Gross Margin |
-225.62% |
| Operating Margin |
-280.75% |
| Profit Margin |
-272.70% |
| FCF Margin |
-203.34% |
| ROA |
-20.36% |
| ROE |
-39.38% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (22)
| Buy |
16 |
| Overweight |
1 |
| Hold |
5 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$105.33*
(68.55% upside)
Low
68.0
Current: $62.49
High
196.0
Target: 105.33
*Average 12-month price target from 18 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 44.67 | 54.58 | 35.43 | 6.16 | 14.08 | 25.42 | 20.18 | 0.34 | 0.88 |
| Revenue Growth | -18.15% | 54.06% | 475.58% | -56.28% | -44.62% | 25.97% | 5835.59% | -61.45% | - |
| Gross Profit | 41.70 | 53.69 | 33.90 | 6.16 | 14.08 | 25.42 | 20.18 | 0.34 | 0.88 |
| Operating Income | -812 | -569 | -333 | -264 | -166 | -60.38 | -24.95 | -23.72 | -15.14 |
| Net Income | -790 | -556 | -336 | -264 | -167 | -48.71 | -25.32 | -23.67 | -15.60 |
| Shares Outstanding | 55.19 | 52.03 | 43.54 | 37.28 | 34.67 | 26.55 | 12.56 | 0.26 | 0.12 |
| Earnings Per Share | -14.31 | -10.68 | -7.71 | -7.07 | -4.81 | -1.83 | -2.02 | -13.79 | -171.59 |
| Operating Cash Flow | -564 | -413 | -281 | -190 | -98.43 | -59.69 | 43.45 | -21.04 | -12.22 |
| Capital Expenditures | -71.03 | -55.74 | -62.24 | -28.03 | -7.06 | -8.71 | -8.67 | -0.87 | -0.40 |
| Free Cash Flow | -635 | -469 | -343 | -218 | -105 | -68.40 | 34.78 | -21.91 | -12.62 |
| Cash & Equivalents | 1,106 | 1,385 | 1,290 | 704 | 518 | 474 | 206 | 67.01 | 29.32 |
| Total Debt | 191 | 153 | 155 | 120 | 61.90 | - | - | - | - |
| Net Cash / Debt | 915 | 1,232 | 1,135 | 584 | 456 | 474 | 206 | 67.01 | 29.32 |
| Assets | 1,727 | 2,243 | 1,901 | 1,118 | 1,002 | 557 | 224 | 69.32 | 30.92 |
| Liabilities | 442 | 358 | 277 | 249 | 152 | 65.48 | 72.72 | 5.23 | 4.22 |
| Book Value | 1,285 | 1,885 | 1,623 | 869 | 850 | 491 | 152 | -55.75 | -55.71 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Bluebird Bio, Inc. |
| Country |
United States |
| Employees |
1,167 |
| CEO |
Nick Leschly |
Stock Information
| Ticker Symbol |
BLUE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BLUE |
| IPO Date |
June 19, 2013 |
Description
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.